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Cleveland, Ohio; Los Angeles, California; New Haven, Connecticut; and New York, New YorkObjectives This study sought to evaluate the short- and long-term outcomes for smokers with
non–ST-segment elevation acute coronary syndromes (NSTE-ACS).
Background Smoking has been associated with the “paradox” of reduced mortality after acute
myocardial infarction (MI). This is thought to be due to favorable baseline characteristics and less
diffuse coronary artery disease (CAD) among smokers.
Methods In the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial,
13,819 patients (29.1% smokers) with moderate- to high-risk NSTE-ACS underwent angiography and,
if indicated, revascularization.
Results Smokers were signiﬁcantly younger and had fewer comorbidities than nonsmokers.
Incidence of death and MI were comparable at 30 days, although smokers had signiﬁcantly reduced
risks of 30-day major bleeding (hazard ratio [HR]: 0.80, 95% conﬁdence interval [CI]: 0.67 to 0.96;
p ¼ 0.016) and 1-year mortality (HR: 0.797, 95% CI: 0.65 to 0.97; p ¼ 0.027). After correction for baseline
and clinical differences, smoking was no longer predictive of major bleeding (odds ratio: 1.06, 95% CI:
0.86 to 1.32; p ¼ 0.56) and was associated with higher 1-year mortality (HR: 1.37, 95% CI: 1.07 to 1.7;
p ¼ 0.013). This pattern of reversed risk after multivariable correction held true for those smokers
requiring percutaneous coronary intervention. Core laboratory angiographic analysis showed that
smokers and nonsmokers were comparable in terms of the extent of CAD, Thrombolysis In Myocardial
Infarction ﬂow, myocardial blush, and the presence of thrombi.
Conclusions In contrast to the paradox previously described in ST-segment elevation MI, our analysis
ﬁnds smoking to be an independent predictor of higher 1-year mortality in patients presenting with
NSTE-ACS, and our angiographic study demonstrates CAD in smokers that is comparable to that in
nonsmokers but evident w1 decade earlier. (Acute Catheterization and Urgent Intervention Triage
Strategy [ACUITY]; NCT00093158) (J Am Coll Cardiol Intv 2014;7:372–9) ª 2014 by the American
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373ST-segment elevation myocardial infarction (STEMI) and
non–ST-segment elevation acute coronary syndromes
(NSTE-ACS) result from similar pathophysiological pro-
cesses but comprise a spectrum of disease severity (1). The
primary difference is that diagnosis of STEMI usually in-
dicates the presence of an occlusive thrombus, with the
paradigm that immediate myocardial reperfusion by
thrombolysis or mechanical revascularization will improve
patient outcome (2). Despite this, recent studies show that
in-hospital and 1-year mortality are similar between the 2
groups (1).See page 380
Abbreviations
and Acronyms
CAD = coronary artery
disease
CI = conﬁdence interval
CK-MB = creatine kinase-
myocardial band
HR = hazard ratio
MI = myocardial infarction
NSTE-ACS = non–ST-segment
elevation acute coronary
syndromes
NSTEMI = non–ST-segment
elevation myocardial
infarction
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis In
Myocardial InfarctionThe U.S. Department of Health and Human Services
estimates that as many as 30% of all coronary heart disease
deaths may be attributed to cigarette smoking (3). Due in
part to the prothrombotic effects of smoking (4), cigarette
smokers are more likely to present with STEMI than with
NSTE-ACS (1,5). Several studies have demonstrated a higher
incidence of acute myocardial infarction (MI) but improved
survival after reperfusion among smokers (6–9). This phe-
nomenon, termed the smoker’s paradox, has been postulated to
be due to the fact that smokers present at a younger age,
typically with fewer comorbidities (6–8), and with a higher
incidence of thrombo-occlusive disease that is optimally
treatable with intravenous thrombolysis (10). Angiographic
evidence suggests that smokers presenting with acute MI also
have less extensive coronary artery disease (CAD) than their
nonsmoking counterparts (11–13). Nevertheless, smoking has
been associated in a dose-dependent fashion with the devel-
opment of coronary artery and aortic atherosclerosis in several
autopsy studies (14,15), and current smoking was recently
conﬁrmed as an independent predictor of greater plaque
burden as assessed by intravascular ultrasound imaging (16).
Smokers account for w20% to 30% of patients with
NSTE-ACS (1,5,17), but few data exist regarding the rela-
tionship between smoking and prognosis in NSTE-ACS.
Given that thrombolysis is not an effective treatment strategy
forNSTE-ACS (18) and that patients with non–ST-segment
elevation myocardial infarction (NSTEMI) typically present
at an older age with signiﬁcantly more cardiovascular
comorbidities than those with STEMI (1), the effect of
smoking on the extent of CAD and prognosis may vary be-
tween populations of patients with different types of ACS.
The ACUITY (Acute Catheterization and Urgent Inter-
vention Triage Strategy) trial (19) enrolled 13,819 patients
with unstable angina and NSTEMI. In the current study, we
evaluated short- and long-term outcomes for smokers with
NSTE-ACS for both the overall study population of the
ACUITY trial and for the subset requiring percutaneous
coronary intervention (PCI). Furthermore, we assessed
angiographic data to correlate outcomes with the magnitude
of vascular disease burden as a function of smoking status.Methods
Study design and protocol. The detailed methodology for
the ACUITY trial was previously published (19). In short,
the study prospectively randomized 13,819 patients with
moderate- to high-risk NSTE-ACS (unstable angina and
NSTEMI) from w600 different centers to receive enox-
aparin or unfractionated heparin plus glycoprotein IIb/IIIa
inhibitors, bivalirudin plus glycoprotein IIb/IIIa inhibitors,
or bivalirudin monotherapy. Inclusion criteria were at least
10 min of cardiac chest pain within 24 h of presentation
in addition to 1 of the following: 1) troponin or creatine
kinase-myocardial band (CK-MB) elevation; 2) dynamic
electrocardiogram changes; or 3) documented previous CAD.
Alternatively, patients with chest pain could be included if
they met all 4 variables for pre-
dicting Thrombolysis In
Myocardial Infarction (TIMI)
risk scores for unstable angina
(20): 1) 65 years of age and older,
2) aspirin taken within the past 7
days; 3) 2 episodes of angina in
the past 24 h; and 4) a history of
3 of the following risk factors:
hypertension, hypercholesterole-
mia, family history of CAD,
diabetes, or current cigarette
smoking.
Angiographic analysis. Coronary
angiography was performed using
a standardized acquisition proto-
col and analyzed by an indepen-
dent angiographic core laboratory
(Cardiovascular Research Foun-
dation, New York, New York).
Complete 3-vessel and lesion-
speciﬁc qualitative and quantita-
tive angiographic analysis and
quantitative left ventriculography were performed using
standardized criteria by reviewers blinded to randomization
assignment and clinical outcome and reviewed for accuracy by
a qualiﬁed physician.Vessel diseasewas deﬁned as quantitative
coronary angiography diameter stenosis 30%. Epicardial
coronary ﬂow was assessed using TIMI ﬂow grade (21) and
correctedTIMI frame count (22).Myocardial blush grade was
assessed before and after PCI based on standard methodology
(23). By protocol, the ﬁrst 7,000 consecutive patients enrolled
in the United States were analyzed by the core angiographic
laboratory.
Endpoint and other deﬁnitions. The primary endpoints
for the present analysis of outcomes among smokers in
the ACUITY trial were 1-year mortality and 30-day
major bleeding (unassociated with coronary artery bypass
surgery). Secondary endpoints were a 30-day composite
Table 1. Baseline Characteristics of ACUITY Patients Based on
Smoking Status
Nonsmokers
(n ¼ 9,614)
Smokers
(n ¼ 3,943) p Value
Age, yrs 65.3  11.1 55.7  10.0 <0.0001
65 54.9 19.5 <0.0001
75 23.0 4.1 <0.0001
Weight, kg 85.5  18.4 85.2  18.7 0.44
Women 31.9 25.2 <0.0001
Diabetes 31.0 20.6 <0.0001
Hypertension, on medication 71.4 55.7 <0.0001
Hyperlipidemia, on medication 60.8 48.1 <0.0001
Anemic 19.7 9.9 <0.0001
Previous MI 32.1 29.0 0.0005
Previous PTCA 40.7 34.2 <0.0001
Previous CABG 20.6 11.1 <0.0001
Family history of CAD 51.0 55.9 <0.0001
Creatinine clearance <60 ml/min 22.8 9.6 <0.0001
LVEF >50% 63.7 60.8 0.0079
UFH/LMWH use before
randomization
62.9 67.4 <0.0001
Aspirin use before randomization 95.9 95.7 0.68
Clopidogrel use before
randomization
52.1 51.1 0.26
Values are mean  SD or %.
ACUITY ¼ Acute Catheterization and Urgent Intervention Triage Strategy; CABG ¼ coronary
artery bypass graft; CAD ¼ coronary artery disease; LMWH ¼ low molecular weight heparin;
LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; PTCA ¼ percutaneous
transluminal coronary angioplasty; UFH ¼ unfractionated heparin.
Table 2. Outcomes Based on Smoking Status at 30 Days and 1 Year
in the ACUITY Trial
Nonsmoker
(n ¼ 9,614)
Smokers
(n ¼ 3,943) p Value
30-day death 155 (1.6) 50 (1.3) 0.14
30-day MI 492 (5.1) 203 (5.1) 0.94
Q-wave MI 100 (1.0) 45 (1.1) 0.60
Non-Q-wave MI 395 (4.1) 158 (4.0) 0.79
30-day urgent TVR 228 (2.4) 109 (2.8) 0.18
30-day death or MI 606 (6.3) 245 (6.2) 0.84
30-day composite ischemia 742 (7.7) 302 (7.7) 0.91
30-day major bleeding 476 (5.0) 157 (4.0) 0.016
1-yr death 386 (4.0) 125 (3.2) 0.027
Values are n (%).
TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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374ischemia endpoint of death, MI, and urgent target vessel
revascularization, and individual components of that com-
posite. These variables have been deﬁned elsewhere (19,24).
Smokers were identiﬁed as patients who reported having
smoked cigarettes within 30 days of randomization.
Statistical analysis. Baseline characteristics and outcomes are
summarized asmeans and SDs for continuous variables and as
frequencies and percentages for categorical variables.Missing/
unknown data values were not imputed, and, in the presen-
tation of categorical variables, denominators excluded un-
known or missing values. The nonparametric Wilcoxon rank
sum test was used for comparison of continuous variables.
Categorical variables were compared using chi-square statis-
tics. A p value <0.05 was considered statistically signiﬁcant.
Univariate analyses were completed for 30-day major
bleeding and 1-year mortality using time-to-event meth-
odology, and the corresponding hazard ratios (HRs) and
95% conﬁdence intervals (CIs) were determined. A multi-
variate Cox proportional hazards regression analysis, which
was selected to take into account time to event data, was
then performed on these variables. Covariates were selected
using a forward stepwise procedure from a large number of
clinical and demographic candidate variables: 65 years of age
and older, smoking status, anemia, study arm, baseline
troponin/CK-MB elevation, baseline creatinine clearance
<60 ml/min, diabetes, electrocardiogram changes, sex,
hyperlipidemia (on medication), hypertension (on medica-
tion), procedure performed, PCI versusmedicalmanagement,
previous MI, previous percutaneous transluminal coronary
angioplasty, previous CABG, and previous angioplasty/PCI.
A signiﬁcance level of 0.15 was required to allow a variable
into the models, and a signiﬁcance level of 0.10 was required
to allow a variable to stay in the models. For overall 1-year
mortality, the ﬁnal model included the following variables:
65 years of age and older, anemia, baseline CK-MB/troponin
elevation, baseline creatinine clearance <60 ml/min, proce-
dure performed, smoking status, diabetes, sex, electrocar-
diogram changes, hypertension (on medication), previous
CABG, and previous MI. All of these variables made it
into the ﬁnal model for 1-year mortality among PCI,
excluding procedure performed, sex, and hypertension (on
medication). The ﬁnal bleeding model included the following
additional variables: previous percutaneous transluminal cor-
onary angioplasty, hyperlipidemia, and study arm randomi-
zation code. All statistical analyses were performed by SAS
version 8.2 (SAS Institute Inc., Cary, North Carolina).
Results
Outcomes based on smoking status for both the overall
population and the subset of patients requiring PCI. Table 1
lists the characteristics of patients based on smoking status.
Smokers were on average a decade younger at presentation,
more commonly men, and more likely to have receivedheparin before randomization compared with nonsmokers.
Smokers alsohad fewer comorbidities: they less commonlyhad
diabetes, hypertension, hyperlipidemia, anemia, renal insufﬁ-
ciency, previous MI, and previous coronary intervention.
Baseline characteristics for smokers and nonsmokers under-
going PCI were similar to those for the overall population.
Table 2 compares 30-day and 1-year outcomes for
smokers and nonsmokers. Smokers had signiﬁcantly lower
incidences of 30-day major bleeding and 1-year mortality.
Table 3. Outcomes for Patients Undergoing PCI Based on Smoking
Status at 30 Days and 1 Year in the ACUITY Trial
Nonsmokers
(n ¼ 5,279)
Smokers
(n ¼ 2,362) p Value
30-day death 60 (1.1) 21 (0.9) 0.33
30-day MI 335 (6.3) 145 (6.1) 0.73
Q-wave MI 55 (1.0) 26 (1.1) 0.82
Non–Q-wave MI 282 (5.3) 119 (5.0) 0.58
30-day urgent TVR 178 (3.4) 85 (3.6) 0.62
30-day death or MI 375 (7.1) 161 (6.8) 0.65
30-day composite ischemia 475 (9.0) 206 (8.7) 0.70
30-day major bleeding 329 (6.2) 124 (5.2) 0.093
1-yr death 183 (3.5) 56 (2.4) 0.013
Values are n (%).
PCI ¼ percutaneous coronary intervention; other abbreviations as in Tables 1 and 2.
Figure 1. Unadjusted Kaplan-Meier Event Rates
Mortality for smokers versus nonsmokers, both for the overall population (A) and fo
(PCI) (B), is demonstrated.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 4 , 2 0 1 4 Robertson et al.
A P R I L 2 0 1 4 : 3 7 2 – 9 Smokers With NSTE-ACS
375When outcomes were compared among the subset of pa-
tients requiring PCI, smokers maintained a signiﬁcantly
lower 1-year mortality, but exhibited only a trend toward
reduced 30-day major bleeding (Table 3). These mortality
differences are illustrated as Kaplan-Meier curves for both
the overall population (3.4% vs. 4.4%) (Fig. 1A) and those
patients undergoing PCI (2.6% vs. 4.0%) (Fig. 1B).
Figure 2 shows the HR and respective CIs for the effect of
smoking on 1-year mortality and 30-day major bleeding that
were derived from both the univariate and multivariate
models. In the univariate model for 1-year mortality,
smoking was associated with a 20% decreased risk in the
overall population (HR: 0.80, 95% CI: 0.65 to 0.98) and a
31% decreased risk among PCI patients (HR: 0.69, 95% CI:
0.51 to 0.92). After accounting for all signiﬁcant covariables,
however, smoking was associated with a signiﬁcant 37%r the subset of patients who underwent percutaneous coronary intervention
Figure 2. Effect of Smoking on 1-Year Death and 30-Day Bleeding for Both the Entire Study Population and the Cohort of Patients Requiring PCI
This graph presents hazard ratios and 95% conﬁdence intervals for the listed outcome variables. Univariate analyses are indicated with solid circles and multivariate
analyses are indicated with open triangles. PCI ¼ percutaneous coronary intervention.
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376increased risk for mortality at 1 year among the overall
population (HR: 1.37, 95% CI: 1.07 to 1.75) and a 28%
increased risk of 1-year mortality among patients undergo-
ing PCI (HR: 1.28, 95% CI: 0.89 to 1.84). Interaction ef-
fects were examined for the covariates in the model, and
although diabetes and previous MI were statistically signif-
icant for death, the fact that there were very few deaths in
each subgroup makes inferences regarding these data
difﬁcult.
Similar trends were seen in the analysis for 30-day major
bleeding (Fig. 2). Univariate models demonstrated 20% and
16% lower risk for smokers in the overall (HR: 0.80, 95%
CI: 0.67 to 0.96) and PCI (HR: 0.84, 95% CI: 0.68 to 1.03)
populations, respectively. After multivariate correction, there
were no signiﬁcant differences in bleeding risks related to
smoking in the overall population (HR: 1.06, 95% CI: 0.86
to 1.32) or among PCI patients (HR: 1.08, 95% CI: 0.86 to
1.37). No interaction effects were noted for the covariates
with respect to 30-day major bleeding.
PCI was required in 7.5% and 7.1% of smokers and
nonsmokers over 1-year follow-up, respectively (HR: 1.067,
95% CI: 0.93 to 1.22; p ¼ 0.35). Similarly, there was no
difference between the 2 groups in the 1-year incidences of
coronary artery bypass graft surgery (1.4% vs. 1.5%, HR:
0.91, 95% CI: 0.67 to 1.25; p ¼ 0.56).
Angiographic comparison of smokers and nonsmokers. As
seen in Table 4, smokers and nonsmokers were largely
comparable in terms of the number of vessels with CAD,
the extent of disease per vessel, TIMI ﬂow, myocardial
blush, and the presence of thrombi. The speciﬁc coronary
arteries with disease are delineated for each population.
Smokers had signiﬁcantly less calciﬁcation and fewer
collaterals present.Smokers more commonly had low TIMI ﬂow (0/1) and
low myocardial blush grade (0/1) pre-PCI (Table 5); how-
ever, angiographic outcomes for smokers requiring PCI were
similar to those for nonsmokers.
Discussion
In this study, we have shown in a large, contemporary
cohort of patients with NSTE-ACS that smoking is an
independent predictor of higher 1-year mortality.
Although univariate analysis suggested a protective effect
of smoking that is similar to that observed among pop-
ulations with STEMI, this mortality advantage of smokers
did not withstand multivariate analysis accounting for
differences in baseline characteristics. This ﬁnding provides
compelling evidence that the smoker’s paradox among
NSTE-ACS patients may be explained in similar fashion
to that seen in patients with acute MI (12). Additionally,
we demonstrated that smokers presenting with NSTE-
ACS have an extent and a complexity of CAD that are
largely comparable to those seen in nonsmokers, despite
disparities in age and other risk factors. These results vary
from what has been previously observed of the relationship
between smoking and mortality and CAD in patients with
STEMI.
The demographic and clinical proﬁles of the smokers
enrolled in the ACUITY trial are comparable to those of
smokers in other large studies of patients with ACS
(5,12,25), although, to our knowledge we are the ﬁrst to
demonstrate that smoking is independently predictive of
higher 1-year mortality after multivariate analysis among
patients with NSTE-ACS. When multivariate regression
was performed on outcomes from the GRACE (Global
Table 4. Angiographic Characteristics of Smokers and Nonsmokers
Nonsmokers Smokers p Value
1-vessel CAD 885/4,846 (18.3) 390/2,047 (19.1) 0.46
LAD disease only 460/4,846 (9.5) 154/2,047 (7.5) 0.0083
LCX disease only 177/4,846 (3.7) 97/2,047 (4.7) 0.037
RCA disease only 248/4,846 (5.1) 139/2,047 (6.8) 0.0070
Lesions per patient 1.53  0.82 1.47  0.75 0.16
2-vessel CAD 1,334/4,846 (27.5) 602/2,047 (29.4) 0.12
LAD and LCX disease 480/4,846 (9.9) 176/2,047 (8.6) 0.097
LAD and RCA disease 577/4,846 (11.9) 257/2,047 (12.6) 0.47
LCX and RCA disease 277/4,846 (5.7) 169/2,047 (8.3) 0.0001
Lesions per patient 3.55  1.51 3.29  1.33 0.0002
3-vessel CAD 2,177/4,846 (44.9) 865/2,047 (42.3) 0.044
Lesions per patient 6.55  2.49 6.04  2.29 <0.0001
Extent of disease/vessel, mm 21.2  15.5 21.0  15.7 0.64
TIMI ﬂow
0/1 1,206/14,235 (8.5) 534/6,041 (8.8) 0.41
2 696/14,235 (4.9) 307/6,041 (5.1) 0.59
3 12,333/14,235 (86.6) 5,200/6,041 (86.1) 0.30
Myocardial blush
0/1 1,124/12,960 (8.7) 473/5,603 (8.4) 0.63
2 1,663/12,960 (12.8) 693/5,603 (12.4) 0.40
3 10,173/12,960 (78.5) 4,437/5,603 (79.2) 0.30
Thrombus present 841/14,302 (5.9) 391/6,059 (6.5) 0.12
LAD morphology
Calcium
None/mild 3,480/4,767 (73.0) 1,629/2,026 (80.4) <0.0001
Moderate 994/4,767 (20.9) 329/2,026 (16.2) <0.0001
Severe 293/4,767 (6.1) 68/2,026 (3.4) <0.0001
Collaterals present 383/4,817 (8.0) 125/2,036 (6.1) 0.010
Ipsilateral 128/385 (33.2) 51/128 (39.8) 0.21
Bridging 97/385 (25.2) 16/128 (12.5) 0.0040
Contralateral 160/385 (41.6) 61/128 (47.7) 0.27
Continued in the next column
Table 4. Continued
Nonsmokers Smokers p Value
RCA morphology
Calcium
None/mild 3,629/4,677 (77.6) 1,617/1,981 (81.6) 0.0003
Moderate 834/4,677 (17.8) 296/1,981 (14.9) 0.0046
Severe 214/4,677 (4.6) 68/1,981 (3.4) 0.023
Collaterals present 787/4,764 (16.5) 348/2,013 (17.3) 0.46
Ipsilateral 9/778 (1.2) 5/349 (1.4) 0.92
Bridging 116/778 (14.9) 47/349 (13.5) 0.59
Contralateral 653/778 (83.9) 297/349 (85.1) 0.68
LCX morphology
Calcium
None/mild 3,960/4,772 (83.0) 1,794/2,028 (88.5) <0.0001
Moderate 692/4,772 (14.5) 203/2,028 (10.0) <0.0001
Severe 120/4,772 (2.5) 31/2,028 (1.5) 0.015
Collaterals present 475/4,810 (9.9) 162/2,033 (8.0) 0.015
Ipsilateral 276/471 (58.6) 96/163 (58.9) 0.95
Bridging 82/471 (17.4) 36/163 (22.1) 0.23
Contralateral 113/471 (24.0) 31/163 (19.0) 0.23
Values are n/N (%) or mean  SD.
CAD ¼ coronary artery disease; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex
artery; RCA ¼ right coronary artery; TIMI ¼ Thrombolysis In Myocardial Infarction.
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377Registry of Acute Coronary Events) database, consistent
with our data, smoking within 30 days of admission was not
a predictor of in-hospital mortality for patients with either
unstable angina or NSTEMI (5), but late mortality was not
examined. In a smaller retrospective study by Castela et al.
(26) consisting of patients with both NSTE-ACS and
STEMI, it was shown that smokers have higher rates of
vascular complications but similar mortality at 1 year. Dif-
ferences between the results of that study and ours may be
attributable to smaller sample size, inclusion of STEMI
patients, and a different deﬁnition of what constitutes a
smoker (i.e., any smoking within the past year) in the
Castela et al. (26) analysis. Other studies have demonstrated
that smoking is associated with an increased relative risk of
cardiovascular death (27) and higher mortality among
younger patients who present with acute MI (28), but these
results are derived from many years of follow-up data rather
than the relatively early 1-year results that we present, andthey are not speciﬁcally representative of patients with
NSTE-ACS. At 1 year, smoking was, in fact, not predictive
of mortality from STEMI in the CADILLAC (Controlled
Abciximab and Device Investigation to Lower Late
Angioplasty Complications) trial (25).
It has been shown that major bleeding has a large impact
on early mortality among patients with NSTE-ACS (29). In
our study, the reduced rates of 30-day major bleeding did not
withstand multivariate analysis. However, neither was an
excess risk of bleeding observed among smokers, suggesting
that the inﬂuence of smoking on mortality may be largely
explained by age and clinical comorbidities.
Atherosclerotic disease of the coronary arteries is known
to have an impact on the development and severity of acute
coronary syndromes. Angiographic CAD burden has been
shown to increase with the number of documented risk
factors in NSTEMI patients (30). Given that smokers with
NSTE-ACS, similar to those with STEMI (12,25), pre-
sented an average of a decade earlier with fewer risk factors
than nonsmokers, one would expect to observe less multi-
vessel disease, higher TIMI ﬂow and myocardial blush
grades, less calciﬁcation, and the development of fewer
collateral vessels in smokers compared with nonsmokers
with NSTE-ACS. Indeed, angiographic substudies of the
GUSTO-I (Global Utilization of Streptokinase and Tissue-
Plasminogen Activator for Occluded Coronary Arteries),
TIMI, and CADILLAC trials demonstrated signiﬁcantly
lower incidences of triple-vessel disease and signiﬁcantly
higher incidences of TIMI 3 ﬂow among smokers with acute
Table 5. Procedural Events for Smokers and Nonsmokers Undergoing PCI
Variables Nonsmokers Smokers p Value
Thrombus 25/2,480 (1.0) 13/1,141 (1.1) 0.72
Spasm 18/2,480 (0.7) 8/1,141 (0.7) 0.93
Abrupt closure 4/2,480 (0.2) 2/1,141 (0.2) 0.92
No reﬂow 4/2,480 (0.2) 1/1,141 (0.1) 0.58
Perforation 1/2,480 (0.0) 1/1,141 (0.1) 0.57
Distal embolization 20/2,480 (0.8) 7/1,141 (0.6) 0.53
Dissection 20/2,480 (0.8) 9/1,141 (0.8) 0.96
Any thrombotic complication 40/2,480 (1.6) 21/1,141 (1.8) 0.62
Any complication 73/2,480 (2.9) 38/1,141 (3.3) 0.53
Baseline TIMI ﬂow
0/1 341/2,491 (13.7) 208/1,140 (18.2) 0.0004
2 284/2,491 (11.4) 112/1,140 (9.8) 0.16
3 1,866/2,491 (74.9) 820/1,140 (71.9) 0.058
Post-PCI TIMI ﬂow
0/1 45/2,475 (1.8) 19/1,140 (1.7) 0.75
2 59/2,475 (2.4) 21/1,140 (1.8) 0.30
3 2,371/2,475 (95.8) 1,100/1,140 (96.5) 0.32
Baseline myocardial blush
0/1 375/2,217 (16.9) 224/1,041 (21.5) 0.0016
2 387/2,217 (17.5) 161/1,041 (15.5) 0.16
3 1,455/2,217 (65.6) 656/1,041 (63.0) 0.15
Post-PCI myocardial blush
0/1 54/2,095 (2.6) 30/1,007 (3.0) 0.52
2 264/2,095 (12.6) 105/1,007 (10.4) 0.080
3 1,777/2,095 (84.8) 872/1,007 (86.6) 0.19
Values are n/N (%).
PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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378STEMI (11,12). These differences were not noted in the
population of smokers from the ACUITY trial.
Our study demonstrates signiﬁcantly more multivessel
disease overall than was observed among patients with
STEMI in the GUSTO-I, TIMI, and CADILLAC trials.
In those trials, smokers and nonsmokers with acute MI had
incidences of triple-vessel disease ranging from 12% to 17%
and 18% to 22%, respectively, compared with incidences of
42% and 45% for the corresponding groups of patients with
NSTE-ACS in the ACUITY trial (11,12,25). Incidences of
multivessel disease in our study are similar to those observed
in a smaller angiographic analysis of 521 patients with ACS
in whom unstable angina accounted for 43% and 60% of
patients in the smoker and nonsmoker groups, respectively
(26). However, variant deﬁnitions of what constitutes vessel
disease could explain some of these differences, so further
studies are required to determine whether the extent of
CAD is greater in smokers who present with NSTE-ACS
compared with acute MI.
We did observe anticipated trends toward less coronary
artery calciﬁcation and collateral vessel formation among
smokers. This was expected because calciﬁc deposits are more
commonly seen in advanced lesions and with increasing age,
but the correlation is not absolute, and the prognosticsigniﬁcance of calciﬁcation is controversial (31). As observed
in our data, the degree of calciﬁcation does not necessarily
correlate with the degree of stenosis, as the progression of
CAD is neither linear nor predictable (32,33). Rapidly
progressing lesions, which are thought to form from plaque
disruption and subsequent thrombus formation of pre-
existing lipid-rich lesions (34,35), may account for up to two-
thirds of patients in whom ACS develops (33,36). The major
predictor of collateral vessel development, on the other hand,
is severity of coronary stenosis (37), but we observed only
modest differences in collateral formation in smokers versus
nonsmokers. Thus, these differences, although signiﬁcant,
are likely of less clinical importance than the measures of
extent and severity of disease discussed previously.
The similarities in the CAD burden between smokers and
nonsmokers are also evident in the proportions of patients
requiring coronary artery bypass graft or PCI. We observed
no difference between groups, but previous studies of ACS
patients that included large percentages of STEMI patients
have demonstrated that smokers are less likely to require
coronary artery bypass graft due to favorable coronary
anatomy (5,26) and more likely to require PCI (5). The
differences observed in our study likely relate to the similar
extent of CAD noted in smokers and nonsmokers with
NSTE-ACS. When the subpopulation of patients who
required PCI was considered, a trend was noted for slightly
more diseased vessels among smokers, although they
responded equally well as nonsmokers to intervention.
Study limitations. First, former smokers were not identiﬁed
by our analysis, and no data were available regarding the
number of cigarettes smoked or smoking status after PCI.
Second, we only had data regarding a subset of the angio-
grams obtained. Third, the number of variables that we are
able to include in our multivariate analysis is limited by the
event rate within the study. The large changes in the HR
estimates of smoking suggests that many covariates inﬂuence
this estimate, and there may be additional confounders that
are not controlled for within our model. Nevertheless, this
is the largest core laboratory analysis to date comparing
smokers and nonsmokers in any patient population, both in
terms of outcomes and angiographic data, and we believe
that we have accounted for the most clinically-relevant
variables in our model.
Conclusions
This study has demonstrated a clear and important impact
of smoking on mortality and development of CAD in pa-
tients with NSTE-ACS. Smoking is associated with the
development of CAD and the presentation with ACS
nearly a decade earlier than in nonsmokers and portends
a signiﬁcant increase in subsequent mortality. NSTEMI
patients are less likely than STEMI patients to be dis-
charged with appropriate pharmacological therapies after
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379hospitalization (1), which could additionally affect disease
progression and prognosis. Because a signiﬁcant population
of NSTE-ACS patients are smokers, our ﬁndings highlight
the importance of continued efforts at smoking cessation
and use of appropriate secondary prevention measures in
this population.
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